Tvardi Therapeutics Inc (fra:69C) Share Price

Company Profile

Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USA
T: +1 713 489-8654
https://www.tvarditherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12

Recommended

These shares are trading at a discount to our fair value discount and have sustainable competitive advantages.

Morningstar | 11 November 2026

There may be meaningful upside as Anthropic is pricing its stock as a reflection of current sentiment, not the company’s fundamentals.

Malik Ahmed Khan, CFA | 11 November 2026

Strong fundamentals meet a demanding valuation.

Esther Holloway | 11 November 2026

Index	Last price	Change	% Change
All Ordinaries	9,243.40	47.90	-0.52%
CAC 40	8,332.87	54.28	0.66%
DAX 40	26,662.77	315.32	1.20%
Dow JONES (US)	52,486.49	254.60	0.49%
FTSE 100	10,835.47	83.88	0.78%
HKSE	24,044.48	271.44	-1.12%
NASDAQ	25,466.19	400.32	1.60%
Nikkei 225	61,592.02	343.43	0.56%
NZX 50 Index	14,256.38	76.52	0.54%
S&P 500	7,619.38	98.45	1.31%
S&P/ASX 200	9,111.10	42.10	-0.46%
SSE Composite Index	3,681.69	1.04	0.03%